Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zeushield Cytotoxic T Lymphocytes in NSCLC
NCT03060343Phase 1Unknown
- Start
- Nov 2016
- Primary completion
- Nov 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zeushield cytotoxic t lymphocytes in non-small cell lung cancer (NSCLC). Primary endpoint: Number of participants with treatment-related adverse events at 8 weeks. Status: unknown.
02
Drugs
zeushield cytotoxic t lymphocytes
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03060343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03060343.